Welcome to Abcentra™

We are a clinical-stage biopharmaceutical company developing first-in-class therapeutics for cardiovascular and inflammatory diseases.

Our pipeline focuses on treating patient populations with substantial residual risk of accelerated atherosclerosis, cardiovascular events, and valve disease as a result of chronic inflammation.

View Our Pipeline

Bullseye Icon

Target Oxidized Lipoproteins

Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.

How It Works

Antibody icon

Treat Inflammatory Disease

Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.

Learn More

Recent News

October 14, 2021

Abcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. Dr. Davidson is currently CEO of New Amsterdam Pharma
Patient lying in bed in background out of focus, IV drip in forground

August 4, 2021

Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial Evaluating Blockade of Oxidized LDL in Psoriasis with Elevated Cardiometabolic Risk

Abcentra LLC announces that the first patients have been dosed in its multi-center phase 2 trial assessing the safety and activity of orticumab.
timothy wright board of directors

August 26, 2020

Timothy Wright Joins Board of Directors

Experienced drug developer and pharma executive, Dr. Timothy Wright, has joined the Abcentra™’s Board of Directors.